

Physician Publications and Presentations

Gynecology Oncology • Holloway

Publications

Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, **Holloway RW**, Method MW, Plaxe SC, Walker JL, Friccius-Queche H, Krasner CN. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study. *Int. J. Gynecol. Cancer* 2014; 24: 1583-1589.

Grendys EC Jr, Florica JV, Orr JW Jr, **Holloway RW**, Wang D, Tian C, Chan J, Herzog TJ. Overview of a chemoresponse assay in ovarian cancer. *Clin. Transl. Oncol.* 2014; 16: 761-769.

James JA, Rakowski JA, Jeppson CN, Stavitzski NM, Ahmad S, **Holloway RW**. Robotic transperitoneal infra-renal aortic lymphadenectomy in early-stage endometrial cancer. *Gynecol. Oncol.* 2014; Dec. 27; In Press. DOI: org/10.1016/j.ygyno.2014.12.028.

Hudry D, Ahmad S, Zanagnolo V, Narducci F, Fastrez M, Ponce J, Tucher E, Lécuru F, Conri V, Leguevaque P, Goffin F, **Holloway RW**, Lambaudie E, Köhler C, Leblanc E, Maggioni A, Vergote I, Houvenaeghel G. Robotically-assisted para-aortic lymphadenectomy: Surgical results - A cohort study of 487 patients. *Int. J. Gynecol. Cancer* 2014; In Press. DOI: [10.1097/IGC.0000000000000373](https://doi.org/10.1097/IGC.0000000000000373).

Al-Badawi IA, Alshankiti H, Ahmad S. Single incision laparoscopic surgery in pregnancy. *CRSLS (Case Report - Society of Laparoendoscopic Surgery)*: 2014; e2014.00404. DOI: [10.4293/CRSLS.2014.00404](https://doi.org/10.4293/CRSLS.2014.00404).

Ansari A, Ahmad S, James JA, Jeppson CN, **Holloway RW**. Robotic-assisted laparoscopic resection of cornual ectopic pregnancy: Description of a surgical technique and review of the literature. *J. Reprod. Med.* 2014; In Press.

Holloway RW, James JA, Ahmad S. Robotic transperitoneal aortic lymphadenectomy: Experience with a single center-docked configuration. In: *Robotics in Gynecology* (Magrina JF, Kho R, Advincula A, Eds.), Wiley & Sons, Hoboken, NJ, 2014; In Press.

Kendrick JE IV, Ahmad S, **Holloway RW**. Robotic pelvic and aortic lymphadenectomy for gynecologic malignancies – One approach. In: *Robotic Surgery: Practical Examples in Gynecology*(Kilic SG, Ertan AK, Kose MF, Eds.), de Gruyter Publisher, Berlin, 2014; pp. 221-236.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski MW, Herraes AC, Martoni AA, Colombo N, **Holloway RW**, Selvaggi L, Li AJ, del Campo JM, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovoman as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--The MIMOSA Study. *Journal of Clinical Oncology* 2013; 32: 1554-1561.

Tran TA, **Holloway RW**. Primary peritoneal low-grade serous carcinoma forming a mass in the colon mimicking a colonic primary carcinoma: A case report. *European Journal of Gynaecological Oncology* 2013; 34: 86-89.

Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, **Holloway RW**, Braly P, Matei D, Einstein MH, Morosky A, Dodion PF, Haluska F. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. *British Journal of Cancer* 2013; 108: 1021-1026.

Brudie LA, Backes FJ, Ahmad S, Zhu X, Finkler NJ, Bigsby IV GE, Cohn DE, O'Malley D, Fowler JM, **Holloway RW**. Analysis of disease recurrence and survival of women with uterine malignancies undergoing robotic surgery. *Gynecologic Oncology* 2013; 128: 309-315.

Secord AA, Geller MA, Broadwater G, **Holloway RW**, Shuler K, Dao N-y, Gehrig PA, O'Malley DM, Finkler NJ, Havrilesky LJ. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIc endometrial cancer. *Gynecologic Oncology* 2013; 128: 65-70.

Holloway RW, James JA, Ahmad S. Robotic transperitoneal aortic lymphadenectomy: Experience with a single center-docked configuration. In: *Robotics in Gynecology* (Magrina JF, Kho R, Advincula A, Eds.), Wiley & Sons, Hoboken, NJ, 2013; In Press.

Backes FJ, **Holloway RW**, Fowler JM. Strategies for avoiding complications from robotic gynecologic surgery. In: *Robotic Gynecologic Surgery* (Kilic SG, Ertan K, Kose F, Eds.), European Publisher, First Edition, 2013; In Press.

Rakowski JA, Tran TAN, Ahmad S, James JA, Brudie LA, Pernicone PJ, Radi MJ. **Holloway RW**. Does a uterine manipulator affect cervical cancer pathology or identification of lymphovascular space involvement? *Gynecologic Oncology* 2012; 127: 98-101.

Kaye S, Fehrenbacher L, **Holloway RW**, Amit A, Karlan BY, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with OC in second or third complete remission. *Clinical Cancer Research* 2012; 18: 6509-6518.

Tran TA, **Holloway RW**. Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma. *International Journal of Gynecological Pathology* 2012; 31: 453-457.

Brudie LA, Gaia G, Ahmad S, Finkler NJ, Bigsby IV GE, Ghurani GB, **Kendrick IV JE**, Rakowski JA, Groton JH, **Holloway RW**. Peri-operative outcomes of patients with stage IV endometriosis undergoing robotic-assisted laparoscopic surgery. *Journal of Robotic Surgery* 2012; 6: 317-322.

Bigsby IV GE, **Holloway RW**, Ahmad S, Sombeck MD, Ebra G, Finkler NJ. Chemoradiation with adjuvant hysterectomy for stage IB-2 cervical cancer: 10 year experience. *Gynecological Surgery* 2012; 9: 327-333.

Holloway RW, Molero Bravo RA, Rakowski JA, James JA, Jeppson CN, Ingersoll SB, Ahmad S. Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: A comparison of colorimetric and fluorescence imaging. *Gynecologic Oncology* 2012; 126: 25-29.

Ingersoll SB, Ahmad S, Finkler NJ, Edwards JR, **Holloway RW**. Cellular therapy for ovarian cancer: Experimental and clinical perspectives. *Current Medicinal Chemistry* 2012; 19: 3787-3793.

Rakowski JA, Ahmad S, **Holloway RW**. Use of pegylated liposomal doxorubicin (PLD) in the management of platinum-sensitive recurrent ovarian cancer: Current concepts. *Expert Review of Anticancer Therapy* 2011; 12: 31-40.

Ramirez PT, Adams S, Boggess JF, Burke WM, Frumovitz MM, Gardner GJ, Havrilesky LJ, **Holloway RW**, Lowe MP, Magrina JF, Moore DH, Soliman PT, Yap S. Robotic-assisted surgery in gynecologic oncology: A Society of Gynecologic Oncology Consensus Statement Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force. *Gynecologic Oncology* 2012; 124: 180-184.

Ingersoll SB, Stoltzfus GP, Merchant MH, Ahmad S, Edwards CR, Ahmed A, Oyer JR, Finkler NJ, **Holloway RW**, Edwards JR. Comparison of cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors or ovarian cancer patients. *Cytotherapy* 2012; 14: 716-723.

Backes FJ, Brudie LA, Farrell MR, Ahmad S, Finkler NJ, Bigsby GE, O'Malley D, Cohn DE, **Holloway RW**, Fowler JM. Short- and long-term complications and morbidity of robotic-assisted comprehensive endometrial cancer staging. *Gynecologic Oncology* 2012; 125: 546-551.

Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, **Holloway RW**, Ingersoll SB, Turkson J. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. *Oncogene* 2012; 31: 2309-2322.

Secord AA, Pokrzywinski R, Havrilesky LJ, Puls LE, **Holloway RW**, Lewandowski GS, Higgins RV, Nycum LR, Kohler MF, Revicki DA. A multicenter, randomized, phase II clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin in sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. *Cancer* 2012; 118: 3283-3293.

Holloway RW, Ahmad S. Robotic-assisted surgery in the management of endometrial cancer. *Journal of Obstetrics & Gynaecology Research* 2012; 38: 1-8.

Holloway RW, Ahmad S. Standardization of one approach to robotic-assisted pelvic and aortic lymphadenectomy for patients with endometrial cancer including the morbidly obese. In: *Proceedings of the 4th Annual Meeting of SERGS (Society of European Robotic Gynecological Surgery)* (Lambaudie E, Narducci F, Eds.), Marseille, France, 2012; pp. 35-43.

Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, **Holloway RW**, Kaja S, Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. *Gynecologic Oncology* 2011; 122: 163-170.

Ingersoll SB, Ahmad S, Stoltzfus GP, Patel S, Radi MJ, Finkler NJ, Edwards JR, **Holloway RW**. Functional characterization of a fluorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models. *International Journal of Gynecological Cancer* 2011; 21: 457-465.

Holloway RW, Brudie LA, Rakowski JA, Ahmad S. Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma: Description of technique. *Gynecologic Oncology* 2011; 120: 419-422.

Basha RM, Baker CH, Sankpal U, Ahmad S, Safe S, Abdelrahim M. Therapeutic applications of non-steroidal anti-inflammatory drugs in cancer: Special emphasis on tolfenamic acid. *Frontiers in Bioscience* 2011; S3: 797-805.

Gaia G, **Holloway RW**, Santoro L, Ahmad S, Di Silverio E, Spinillo A. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: A systematic review. *Obstetrics & Gynecology* 2010; 116: 1422-1431.

Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S. Tolerability, efficacy, and safety of pegylated liposomal doxorubicin in combination with carboplatin versus gemcitabine/carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: A systematic review. *The Oncologist* 2010; 15: 1073-1082.

Holloway RW. Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer [Letter-to-the-Editor]. *Gynecologic Oncology* 2010; 116: 147-148.

Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli RL, **Holloway RW**, Bristow RE. Correlation of extreme drug resistance assay results and progression-free survival following intra-peritoneal chemotherapy for advanced ovarian cancer. *Journal of Chemotherapy* 2010; 22: 270-274.

Holloway RW, Ahmad S, DeNardis SA, Peterson LB, Sultana N, Bigsby GE IV, Pikaart DP, Finkler NJ. Robotic-assisted laparoscopic hysterectomy with lymphadenectomy for endometrial cancer: Analysis of surgical performance. *Gynecologic Oncology* 2009; 115: 447-452.

Mendivil A, **Holloway RW**, Boggess JF. Emergence of robotic assisted surgery in gynecologic oncology. *Gynecologic Oncology* 2009; 114: S24-S31.

Holloway RW, Patel SD, Ahmad S. Robotic surgery in gynecology. *Scandinavian Journal of Surgery* 2009; 98: 96-109.

Schilder RJ, Pathak HB, Lokshin AE, **Holloway RW**, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. *Gynecologic Oncology* 2009; 113: 21-27.

Ingersoll SB, Patel S, Caballero L, Ahmad S, Edwards D, **Holloway RW**, Edwards JR. Synergistic cytotoxicity of interferon- α 2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy. *Gynecologic Oncology* 2009; 112: 192-198.